Abbexa

Abbexa

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.2M

Overview

Abbexa is a private, commercial-stage supplier of essential life science research reagents headquartered in Cambridge, UK. Operating as a B2B distributor and manufacturer, it offers a vast catalog of over 300,000 products, including antibodies, ELISA kits, and proteins, targeting academic and industrial research markets. The company generates revenue through direct sales and has established a significant online presence with distribution support in the US and UK. Its strategy focuses on providing a broad range of reliable and validated research tools to support biomedical discovery.

OncologyMetabolic DiseaseInfectious DiseaseCardiovascularOphthalmology

Technology Platform

Commercial and production infrastructure for biological reagents, including antibody development, immunoassay (ELISA/CLIA) kit production, protein/peptide synthesis, and custom multiplex assay services.

Funding History

2
Total raised:$6.2M
Series A$5M
Seed$1.2M

Opportunities

The global demand for validated research reagents is driven by sustained biomedical R&D funding and the need to address the reproducibility crisis in science.
Growth in biomarker discovery, biologics development, and geographic expansion into new research markets present significant avenues for catalog expansion and increased market share.

Risk Factors

Abbexa faces intense competition in a fragmented market, risking price pressure and commoditization of its core products.
It is also dependent on the stability of global research funding and faces operational risks related to maintaining consistent quality in biological reagent production at scale.

Competitive Landscape

Abbexa competes in the crowded life science reagents market against giants like Abcam and Thermo Fisher Scientific, as well as numerous specialized smaller firms. Its strategy relies on offering a broad catalog, competitive pricing, and responsive service to differentiate itself, rather than competing on a single proprietary technology platform.